In the absence of a driver mutation, chemotherapy is the standard treatment option as first-
and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large …

Chemotherapy is the standard treatment of in advanced lung adenocarcinoma patients
without driver mutation. However, few drugs could be selected when diseases progressed …

Background: Apatinib is a tyrosine kinase inhibitor (TKI) that selectively inhibits the vascular
endothelial growth factor receptor-2. A weighted pooled analysis was performed to evaluate …

Background Apatinib, a small‐molecule inhibitor of vascular endothelial growth factor
receptor 2 (VEGFR‐2), has proven to be effective and safe for treating patients with …

Few pieces of evidence have been published on the use of Apatinib Mesylate (AM) against
EGFR-TKI resistance in lung adenocarcinoma (LA) patients. Here, we investigate the clinical …

Although targeted therapy directed toward driver mutations has produced a significant
efficacy benefit for patients with non-small cell lung cancer (NSCLC), many patients do not …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)-
rechallenged therapy for EGFR-mutant non-small cell lung cancer (NSCLC) patients who …

Background Dual blockade of both EGFR and VEGFR pathways in EGFR‐mutant NSCLC
have shown enhanced antitumor efficacy versus EGFR‐TKIs alone. Apatinib is an orally …

Background This study was designed to assess the clinical efficacy and toxicity of apatinib
(YN968D1) as third or subsequent‐line treatment for stage III/IV non‐small cell lung cancer …

Although many strategies have been developed for non-small cell lung cancer (NSCLC),
more secondary and further treatments are needed due to drug resistance or tumor …